GlassScriptPhysician profile
Shaina Adelman
NPI 1518505650
$325.30
in general payments reported to CMS, 2019-2025
11 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $69.10 · 2023: $23.80 · 2024: $19.78 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $256.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $61.66 | 2025 | Erleada |
| Fresenius USA Marketing, INC. | $39.49 | 2022-2023 | Velphoro, Korsuva |
| Stemline Therapeutics INC. | $36.42 | 2025 | Orserdu |
| Amgen INC. | $30.41 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.77 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.38 | 2025 | Vpriv |
| Nxstage Medical, INC. | $23.00 | 2022 | |
| Pharmaand Gmbh | $22.13 | 2025 | Rubraca |
| Verastem, INC. | $21.55 | 2025 | Avmapki Fakzynja Co-Pack |
| Abbvie INC. | $19.78 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $14.71 | 2025 | Tagrisso |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaina Adelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.